Non-Alcoholic Fatty Liver Disease And Its Role As A Link Between Gastroenterology And Cardiovascular Risk.

Abstract

Background Non-alcoholic fatty liver disease (NAFLD) is described as the hepatic accumulation of fat in people with little or no alcohol intake. It goes hand in hand with cardiovascular disease metabolic abnormalities, and it is one of the main risk factors of cardiovascular disease causing a global burden to public health.

Objectives: to explore the interrelationship between NAFLD and cardiovascular risk factors through the investigation of the prevalence of NAFLD, the clinical outcomes associated with NAFLD, and the possible pathways connecting NAFLD and cardiovascular morbidity.

Methodology: This prospective cohort study conducted at Department of Medicine, LRH-MTI, Peshawar from jan 2020 to june 2020. targeted 100 patients who had been diagnosed with NAFLD and confirmed through liver ultrasonography and none of them had serious alcohol consumption. There were clinical and laboratory data such as age, sex, medical history, liver functionality tests, lipid profiles, blood pressure, and fasting glucose. The Framingham Risk Score was used to determine cardiovascular risk. The SPSS version 20.0 was used to carry out statistical tests, such as correlation and regression, to test the hypotheses on association between NAFLD severity and cardiovascular risk factors.

Results: Out of 100 patients 75 %t had metabolic syndrome, and the most common of them were hypertension and dyslipidemia. Patients with moderate to severe NAFLD had Higher Framingham Risk Scores (p = 0.03). Fatty liver disease of the non-alcoholic type was largely linked to the presence of high blood pressure, hypercholesterolemia, and insulin resistance.

Conclusion: NAFLD has a close relationship with augmented cardiovascular danger and it occurs via metabolic failure, hypertension and dyslipidemia. These results imply the significance of cardiovascular risk assessment and management among NAFLD patients at early stages. Comprehensive interventions aimed at hepatic and cardiovascular health can reduce the adverse outcomes and enhance patient outcomes.